Literature DB >> 15947801

Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration.

Alejandro Oliver-Fernandez1, Jeff Bakal, Shaun Segal, Gaurav K Shah, Ashish Dugar, Sanjay Sharma.   

Abstract

PURPOSE: To determine whether the time elapsed from initial (referral) diagnosis of neovascular (wet) age-related macular degeneration (AMD) to assessment and treatment by a retinal specialist is associated with visual deterioration in the intervening period.
METHODS: A prospective pilot study of 38 consecutive AMD patients who presented with newly diagnosed subfoveal choroidal neovascularization was conducted in a tertiary care retinal practice. All eligible subjects underwent clinical examination and digital fluorescein angiography at the time of assessment by a retinal specialist. Correlations were performed to assess the association between continuous independent variables and any visual deterioration since initial diagnosis. Multivariate linear regression models with stepwise techniques were used to evaluate any association between visual progression and time elapsed, while controlling for potential clinical covariates.
RESULTS: Of the 38 patients, 32 (84%) met the inclusion and exclusion criteria; no differences in important variables were noted between those included and those excluded. The median time between initial diagnosis and referral assessment and treatment was 28 days (interquartile range=36.5 days); some degree of visual loss developed in 14 (44%) of the subjects. The elapsed time was correlated with progression of visual loss (r=0.50, p=0.003). Multivariate linear regression demonstrated that only time elapsed and lesion type based on fluorescein angiography were associated with progression of visual loss (R2=0.491, F(4,28)=6.744, p=0.001); lesion size, age and sex were not significantly associated with progression of visual loss.
INTERPRETATION: Delay in assessment and treatment of new-onset wet AMD by a retinal specialist is associated with a higher risk of visual loss.

Entities:  

Mesh:

Year:  2005        PMID: 15947801     DOI: 10.1016/S0008-4182(05)80074-2

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  17 in total

1.  Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity.

Authors:  Philipp Sebastian Muether; Manuel M Hermann; Konrad Koch; Sascha Fauser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-09-24       Impact factor: 3.117

Review 2.  Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis.

Authors:  G Pron
Journal:  Ont Health Technol Assess Ser       Date:  2014-08-01

3.  Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes.

Authors:  Yannis M Paulus; Joan L Jefferys; Barbara S Hawkins; Adrienne W Scott
Journal:  Qual Life Res       Date:  2017-03-29       Impact factor: 4.147

Review 4.  Defining response to anti-VEGF therapies in neovascular AMD.

Authors:  W M Amoaku; U Chakravarthy; R Gale; M Gavin; F Ghanchi; J Gibson; S Harding; R L Johnston; S P Kelly; S Kelly; A Lotery; S Mahmood; G Menon; S Sivaprasad; J Talks; A Tufail; Y Yang
Journal:  Eye (Lond)       Date:  2015-04-17       Impact factor: 3.775

5.  The significance of early treatment of exudative age-related macular degeneration: 12 months' results.

Authors:  Birgit Weingessel; Gregor Hintermayer; Saskia M Maca; Renate Rauch; Pia Veronika Vecsei-Marlovits
Journal:  Wien Klin Wochenschr       Date:  2012-10-24       Impact factor: 1.704

6.  Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration.

Authors:  Tae Gon Lee; Jae Hui Kim; Young Suk Chang; Chul Gu Kim; Jong Woo Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-11       Impact factor: 3.117

7.  Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy.

Authors:  Pearse A Keane; Adnan Tufail; Praveen J Patel
Journal:  J Ophthalmol       Date:  2011-11-22       Impact factor: 1.909

8.  Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis.

Authors:  Handan Canan; Selçuk Sızmaz; Rana Altan-Yaycıoğlu; Cağla Sarıtürk; Gürsel Yılmaz
Journal:  Clin Interv Aging       Date:  2014-01-10       Impact factor: 4.458

9.  UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12.

Authors:  Aaron Y Lee; Cecilia S Lee; Thomas Butt; Wen Xing; Robert L Johnston; Usha Chakravarthy; Catherine Egan; Toks Akerele; Martin McKibbin; Louise Downey; Salim Natha; Clare Bailey; Rehna Khan; Richard Antcliff; Atul Varma; Vineeth Kumar; Marie Tsaloumas; Kaveri Mandal; Gerald Liew; Pearse A Keane; Dawn Sim; Catey Bunce; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2015-02-13       Impact factor: 4.638

10.  Ocular Risk Factors for Exudative AMD: A Novel Semiautomated Grading System.

Authors:  João Pedro Marques; Miguel Costa; Pedro Melo; Carlos Manta Oliveira; Isabel Pires; Maria Luz Cachulo; João Figueira; Rufino Silva
Journal:  ISRN Ophthalmol       Date:  2013-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.